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We have investigated the possibility that metabolism of arachidonic acid by the lipoxygenase pathway contributes to ADP-evoked rises in [Ca:+], 
in human platelets. 301tM BW A4C did not affect ADP-evoked Ca 2" signals, but inhibited 12-1ipoxygenase activity in platelet homogenates. Another 
lipoxygenase inhibitor, MK 866 was similary without effect on ADP-evoked Ca-'* signals. ADP was found to liberate little arachidonic acid. and 
formation of the lipoxygenase product 12-HETE was not detectable. The rise in [CaZ÷]~ evoked by arachidonic acid was completely inhibited by 
the cyclooxygenase inhibitor,s aspirin or indomethacin. These results indicate that lipoxygenase products do not play an essential role in mediating 
rises in lCa"*]~ evoked by ADP, or by araehidonie acid. 
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1. INTRODUCTION 
Platelet activation by various agonists is accompa- 
nied by the liberation of arachidonic acid which is sub- 
sequently metabolised by cycloxygenase and lipoxyge- 
nase pathways [1]. One of the main cycloxygenase prod- 
ucts, TxA 2, iS reeognised as having an important auto- 
coid role, itself stimulating the hydrolysis of phosphati- 
dylinositol 4,5-bisphosphate and elevating [CaZ+]~ [2,3]. 
These actions reinforce the primary stimulus, but, with 
the exception of activation by collagen, are not essential 
for an elevation in [Ca2+]~, which can occur when cyclo- 
xygenase is inhibited using aspirin or indomethacin 
[4,5]. 
Recently, it has been suggested that the metabolism 
of arachidonic acid by the lipoxygenase pathway plays 
a crucial role in ADP-evoked Ca~'*-signal generation 
and aggregation i  human platelets [6]. This proposal 
was based on the finding that NDGA and BW 755C, 
which have lipoxygenase-inhibiting activity, suppressed 
ADP-evoked activation. However, the specificity of 
these compounds is relatively poor, for example BW 
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755C has similar inhibitory effects on lipoxygenase and 
cycloxygenase activity [7]. The proposal that lipoxyge- 
nase products play a crucial intermediary role in the 
ADP response contrasts with evidence that this agonist 
can elevate [Ca2~]i without measurable delay (~<30 ms) 
in human platelets [8.9], apparently by opening recep- 
tor-operated non-selective cation channels in the plas- 
ma membrane [10]. 
Here we report a re-examination of the role of the 
lipoxygenase pathway in the generation of Ca -'+ signals 
evoked by ADP and arachidonic acid in human plate- 
lets co-loaded with fura-2 and BAPTA. We have com- 
pared the effects of NDGA with those of the more 
specific lipoxygenase inhibitors BW A4C [7] and MK 
866 [8] on basal [Ca2"]i and on ADP-evoked changes. A
contribution of the lipoxygenase pathway to Ca -'+ signal 
generation following the metabolism of arachidonic 
acid was also tested for by comparing responses before 
and after cycloxygenase inhibition using aspirin or in- 
domethacin. 
2. EXPERIMENTAL 
Platelet-rich plasma was prepared as previously described [4]. After 
the addition of apyrase (20 ,ttg/ml) and, if appropriate, aspirin (I00 
,ttM), the cells were loaded with fura-2 and BAPTA by incubation with 
fura-2/AM (5 pM) and BAPTA/AM (10/aM) for 45 rain at 37°C. 
(Cells were co-loaded with BAP'rA to increase cytosolic Ca 2. buffer- 
ing and make any inhibition of Ca:" signal generation easier to detect.) 
Platelets were then collected by centrifugation and resuspended in
HEPES-buffered saline of composition (in raM): 145 NaCI, 5 KCI, 
1 MgSO4, 10 Na-HEPES, pH 7.4, at 37°C. When investigating the. 
effects of cycloxygenase inhibition, the previously untreated cell sus- 
pension was divided and half w~ts treated with aspirin (100 ,uM) or 
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indomethacin (15 pM) for 15 min before use. In other experiments. 
all the cells were pretreated with 100 pM aspirin to exclude any 
contribution of the eyeloxygenase pathway to ADP-evoked responses. 
Fura-2-fluorescence was recorded from aliquots of platelet suspen- 
sion placed in cuvettes in a modified Perkin-Elmer MPF 44A Spec- 
trophotometer. The suspension was thermostatically controlled at 
37°C and stirred by a magnetic bar. I mM CaClz was added to each 
aliquot before use. The fluorescence signal, with excitation at 339 nm 
and emission at 500 nm was calibrated in terms of[CaZ+]+ as previously 
described [5]. 
The conversion of [l~C]arachidonie acid to t~C-labelled 12-HETE 
by platelet homogenate was determined essentially as previously de- 
scribed [7]. The percentage conversion to 12-HETE was calculated 
following quantification of activity on TLC plates using a Phosphor 
lmager (Molecular Design Ltd). For experiments with intact platelets, 
the cells were pre-labelled by incubating washed suspensions with 
[~4C]arachidonic a id (0.I pCi/ml) for I h, followed by a further centri- 
fugation and resuspension. Lipids were extracted and analysed as for 
homogenates. 
NDGA, BW A4C and MK 866 were added from stocks in DMSO 
by 1000-fold dilution; aspirin and indomethacin were similarly added 
from stocks in methanol. The vehicles were without significant effect. 
Arachidonate was added from a 100 mM stock prepared by dissolving 
arachidonic acid in 125 mM NaOH. ADP was added from a I0 mM 
stock in HEPES-bulTcred saline. 
Aspirin, arachidonic acid and indomethacin were from Sigma 
(Poole. UK), NDGA was obtained from Sigma and Aldrich (Gillin- 
gham, UK), Fura-2/AM and BAPTA/AM were from Molecular 
Probes (Eugene, OR, USA). [l-t=C]arachidonic acid was from 
Amersham International (Amersham, UK). BW A4C and MK 866 
were gifts from Dr. Laurence Garland, Welleome Research Labo- 
ratories (Beckenham, UK). 
3. RESULTS AND DISCUSSION 
3. l. Effects of NDGA and 4-bromophenylacyl bromide 
NDGA from Sigma had little inhibitory effect on 
rises in [Ca2÷]i evoked by 10/.tM ADP at concentrations 
up to 10pM (Figs. la and 2a). At higher concentrations 
(930 pM), the NDGA itself elevated [Ca2+]~, and the 
subsequent ADP-evoked response was reduced (Figs. 
lb and 2a). In view of the activitation of the cells by this 
batch of NDGA, we also obtained this compound from 
another source (Aldrich). Again we found that higher 
concentrations (I>30 pM) of NDGA elevated [Ca2+]i 
(Fig. lc), although with this batch of compound some 
reduction in ADP-evoked rises in [Ca~-+]~ ,,'~ observed 
at 10 pM and inhibition was nearly complete z,~ 30 pM 
(Figs. lc and 2b). We also attempted to use 4-bromo- 
phenylacyl bromide, an inhibitor of phospholipases A~ 
and C, which Borin et al. [6] reported to inhibit 
responses evoked by ADP. However, we found that this 
compound itself induced large rises in [Ca2+]~ which 
made it impossible to assess its effects on ADP-evoked 
rises in [Ca-'+]i (not shown). 
These results contrast with those of Borin et al. [6] 
who report almost complete inhibition of ADP-evoked 
rises in [Ca:+]~ by 10pM NDGA and do not refer to any 
effects of the compound itself on [Ca2+]~. We cannot 
readily explain these differences, although they may 
arise from the use of quin-2-1oaded platelets rather than 
fura-2-1oaded cells, and the storage of cells at reduced 
pH by Borin et al. [6]. 
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Fig. 1. Effects of NDGA on resting and ADP-evoked rises in [Ca;+]+. 
NDGA at the shown concentrations from Sigma (a,b) or Aldrich (c) 
and ADP (10 #M) were added as indicated by the arrows. 
3.2. Effects of selective lipoxygenase inhibitors 
In view of the difficulties in assessing the inhibitory 
action on the ADP response when NDGA itself acti- 
vated the cells, and in the light of the known poor 
specificity of this compound [7], we turned to the more 
selective compound BW A4C. This has been reported 
to inhibit [~4C]12-HETE production from [~4C]arachi- 
donic acid in platelet homogenates with an IC50 of 1.2 
/~M [7]. We also assessed the effect of the compound 
MK 866, which inhibits 5-1ipoxygenase by blocking the 
translocation of the enzyme to the membrane protein 
FLAP with a reported ICso around 1 nM [11,12]. Al- 
though platelets lack 5-1ipoxygenase, the possible role 
of FLAP in the activation of platelet 12-1ipoxygenase 
has yet to be determined. 
BW A4C had no significant effect on the rise in [CaZ+]+ 
evoked by 10/.tM ADP at concentrations up to 30 tiM 
(Figs. 2(; and 3a). This concentration of the compound 
reduced the conversion of [~4C]arachidonic a id to 
[J4C] 12..HETE by platelet homogenates to about 15% of 
the control value, confirming its potency as an inhibitor 
of 12-1ipoxygenase (Fig. 4). MK 866, at concentrations 
up to 100 nM, was without effect on the rises in [Ca~+]+ 
evoked by 10pM ADP (Figs. 2d and 3b). These results 
indicate that the lipoxygenase pathway plays no essen- 
tial role in the ADP-evoked rise in [Ca2+]i. 
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Fig. 2. Dose-response r lationships for the effects on ADP-evoked rises in [Ca2~]~ of (a) NDGA (Sigma), (b) NDGA (Aldrich), (c) BW A4C and 
(d) MK 866. Results are expressed as the mean + SE of the rise in [Ca'*]~ above the pro-stimulus level evoked by 10/JM ADP after 5 rain 
pro-incubation with the inhibitor, compared with that evoked in paired controls. 
3.3. 12-HETE production 
ADP is a comparatively weak platelet agonist, for 
example in terms of its ability to stimulate phospholi- 
paso C [13,14] or to stimulate the second phase of aggre- 
gation in the absence of thromboxane A2 formation 
[ 15,16]. We therefore investigated the ability of ADP to 
evoke the production of 12-HETE in platelets pro-la- 
belled with [~4C]arachidonic acid. There was no detecta- 
ble production of 12-HETE in response to 10/.tM ADP 
(not shown). This finding is in agreement with other 
reports that ADP evokes little or no eicosanoid forma- 
tion [17], and further indicates the lack of a role for 
lipoxygenase in the ADP response. 
3.4. Effects of arachidonic acid 
Although our results indicate that metabolism of ara- 
chidonic acid by the lipoxygenase pathway plays no role 
in the generation of platelet Ca 2÷ signals evoked by 
ADP, this does not rule out a contribution of this path- 
way to the responses evoked by other agonists which 
may be more potent liberators of arachidonate. We 
therefore attempted to reveal any contribution of the 
lipoxygenase pathway to the rise in [Ca2*]~ evoked by 
arachidonic acid by blockade of the contribution of the 
cyclooxygenase pathway using aspirin or indomethacin. 
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We also determined the effects of these inhibitors on the 
ADP response. The results are shown in Fig. 5. 
The addition of I0/,tM arachidonic acid evoked a rise 
in [Ca~+]i of 606 _ 86 nM above the basal level, com- 
pared with a rise of  only 5 + I nM in paired controls 
pretreated with 100 nM aspirin (SE, n=8). Similarly, 
pretreatment with 15/,tM indomethacin reduced the rise 
in [Ca:+]i evoked by 10/.tM arachidonic acid from 661 
+ 48 nM to only 6 ___ 1 nM in paired control (SE, n=8). 
In contrast, 100/.tM aspirin only resulted in a reduction 
in the rise in [Ca2÷]~ evoked by 10/tM ADP from 416 
+ 78 nM to 364 + 53 nM (SE, n=9). Indomethacin (15 
/~M) reduced the rise in [Ca:÷]~ evoked by 10/~M ADP 
from 593 + 56 nM to 360 + 18 nM (SE, n=8). 
These results indicate that conversion of arachidonic 
acid by the lipoxygenase pathway does not contribute 
to the rise in [Ca2÷]~ evoked by this eicosanoid, and that 
the response is almost entirely accounted for by cycle.. 
xygenase activity. 
4. CONCLUSIONS 
These results provide persuasive evidence that inhibi- 
tion of 12-1ipoxygenase does not suppress ADP-evoked 
Ca 2+ signals in human platelets, and that 12-1ipo- 
Volume 292, number 1,2 FEBS LE'I~rERS November 1991 
(a) 
1000~ 
¢ 500~ 
~1 200 
.o. ~ 0 o - -  
tb ]  
1000 
v ¢ 500  
% 200 - -  
,~ ,  
100 
t t t t 
DMSO ADP BW A4O ADP 
t t t t 
DMSO AOP MK 866  ADP 
2 mln 
Fig. 3. Lack of effect of (a) 30/.tM BW A4C and (b) 100 nM MK 866 
on rises in [Ca~÷]i evoked by 10 I~M ADP. 
xygenase products  are not key steps in this s ignal l ing 
pathway.  Fur thermore ,  the present  results emphas ise  
the crucia l  ro le o f  cyc looxygenase products  in Ca  2+ 
signals evoked by arach idon ie  acid,  and the v i r tua l  
absence o f  Ca  -'+ responses to a rach idonate  when selec- 
t ive cyc loxygenase inh ib i tors  are present.  
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